Abstract: 　　With the growing understanding of epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC) and the emergence of new clinical data from targeted therapies, the Chinese Society of Clinical Oncology (CSCO)
　　NSCLC Expert Committee has updated the 2023 Chinese expert consensus. Based on the latest domestic and international literature, clinical evidence, and expert experience, the "Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)" introduces refinements in the diagnostic and therapeutic strategies for this rare mutation. This article highlights the key updates and recommendations in the 2024 consensus compared to the 2023 version and outlines future directions to optimize clinical practice and improve patient outcomes.